- WKN: 704230
- ISIN: DE0007042301
- Land: Deutschland
Nachricht vom 08.11.2019 | 07:04
RHÖN-KLINIKUM AG Confirms Guidance for 2019 Following Increase in Revenues in the Third Quarter and in the First Nine Months
DGAP-News: RHÖN-KLINIKUM AG
/ Key word(s): Quarter Results/Quarter Results
Stephan Holzinger, CEO of RHÖN-KLINIKUM AG, stated: "We are only partially satisfied with our results for the first nine months. In comparison with the first six months of 2019 we are now also facing operative challenges at most of our sites. We are already approaching the challenges systematically by urgently implementing specific staffing, organisational and technical measures which are designed to improve our operative performance and maintain our leading position in a competitive market. Our investments and strategic projects, such as starting the second stage of construction at our campus in Bad Neustadt and the building projects at the university hospitals in Giessen and Marburg, are well on schedule. We are pleased to report that there is growth in our acute medical care."
Increase in Revenues - Operative Earnings and Net Consolidated Profit as Expected to be Lower Than Last Year
Revenues rose by 4.6 % to Euro 970.8 million in the first nine months of 2019. The strong growth in revenues mainly came from our acute medical care. Earnings before interest, taxes, depreciation and amortisation (EBITDA) dropped by 4.9 % to Euro 97.5 million following Euro 102.5 million in the same period of last year. The EBITDA margin stood at 10.0 % after 11.0 % in the previous year. Net consolidated profit amounted to Euro 37.8 million after Euro 47.6 million last year.
It should be taken into consideration with respect to the drop in EBITDA that the third quarter of last year was influenced by a positive one-off effect on EBITDA in the amount of Euro 20 million from the agreement on separate accounting at the university hospitals in Giessen and Marburg. Increased earnings from the university out-patient clinics in Giessen and Marburg as well as subsequent effects from the Fresenius/Helios transaction had a positive effect on EBITDA in the first nine months of financial year 2019. The improvement programme which we initiated in 2017 and which has since been implemented throughout our corporate group also contributed significantly to the development of our results and also secured the results.
With 71.6 % the equity ratio continues at a very high level. As part of its long-term financial strategy RHÖN-KLINIKUM AG exploited the favourable interest rate environment in July 2019 and issued registered bonds with a total nominal value of Euro 60.0 million and a term of 20 years. Our company has now a strong financial foundation with a syndicated credit line, a promissory note loan as well as the registered bond.
Strategic Projects - Second Stage of Construction at Campus in Bad Neustadt
The first nine months were characterised by start-up effects in providing forward-looking and improved healthcare at the new campus in Bad Neustadt. The fusion and cultural integration of four clinics which had been working independently from each other for decades , the new teams which needed to establish themselves, the new arrangements in the medical and organisational processes as well as technical challenges all took up a little more time than originally expected. Also, the reduction in the number of patients at the beginning of the year which was associated with the move initially had a noticeable effect on the development of the operative results.
As part of the redevelopment of our campus site in Bad Neustadt the second stage of construction has been started with, among other things, the addition of an in-patient rehab unit for the psychosomatic clinic. RHÖN-KLINIKUM AG has therefore acknowledged the growing demand for such services. As of 1st January 2020 we shall add neurosurgery to our range of services at our site. We have also been able to win renowned senior physicians for important specialist areas at our other sites.
Preparations on Schedule for the Start of Medgate Deutschland
RHÖN-KLINIKUM AG will soon be represented on the growing telemedicine market with Medgate Deutschland. The Investment, Strategy and Finance Committee of the Supervisory Board of RHÖN-KLINIKUM AG with the power of resolution has approved the establishment of a joint company called Medgate Deutschland GmbH with the telemedicine provider Medgate. A unanimous resolution by the Board of RHÖN-KLINIKUM AG was also passed prior to the unanimous resolution by the Supervisory Board. RHÖN-KLINIKUM AG will hold a majority stake of 51 % of the shares of the new company which will be registered in Germany. Medgate which is registered in Basel will hold 49 % of the shares. In future Medgate Deutschland will provide patients with advice and treatment within the German regulatory framework for both urgent and/or general medical questions via telephone, video, internet and a smartphone app in an initial expansion stage. RHÖN-KLINIKUM AG has already been using telemedical processes for many years in preclinical trials, in-patient and out-patient care and also in the after-care process. Medgate Deutschland is a sensible strategic addition to our portfolio.
Confirmation of Guidance
Our guidance for 2019 is confirmed. RHÖN-KLINIKUM AG expects revenues in the amount of Euro 1.30 billion +/- 5 % for the current financial year. We also expect earnings before interest, taxes, depreciation and amortisation (EBITDA) in the range of Euro 117.5 million to Euro 127.5 million.
Due to tighter nursing legislation, such as the German regulation for the threshold for nursing staff (Pflegepersonaluntergrenzen-Verordnung) and the German nursing staff reinforcement act (Pflegepersonalstärkungsgesetz) RHÖN-KLINIKUM AG currently assumes that its corporate group will be burdened with an additional low two-digit million amount in financial year 2020.
Due to our large sites with highly specialised centres we can react better to changes and growing demands than the overall healthcare market.
RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. The hospital group offers excellent medical care with a direct link to universities and research institutes. More than 850,000 patients are treated every year at the five group hospitals located in Bad Berka, Bad Neustadt, Frankfurt (Oder), Giessen and Marburg where more than 17,000 employees work. With the RHÖN campus concept the Company is currently implementing a new and forward-looking project which raises fully comprehensive healthcare in rural areas to a new level of excellence and is geared to the growing needs of patients.
More information under www.rhoen-klinikum-ag.com
RHÖN-KLINIKUM AG | Head of Corporate Communications and Marketing
RHÖN-KLINIKUM AG | Head of Investor Relations and Treasury
RHÖN-KLINIKUM AG | Schlossplatz 1 | 97616 Bad Neustadt / Saale, Germany
|Salzburger Leite 1|
|97616 Bad Neustadt a.d.Saale|
|Phone:||+49 (0)9771 - 65-0|
|Fax:||+49 (0)9771 - 97 467|
|Listed:||Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange|
|EQS News ID:||908015|
|End of News||DGAP News Service|
Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv
Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.
Der AKTIONÄR News
05. August 07:30 BMW rutscht in die roten Zahlen – kommt jetzt das Kaufsignal?
05. August 06:25 Allianz weiter ohne Prognose – Aktie jetzt verkaufen?
05. August 06:20 Nikola-Aktie bricht ein: Das ist zu wenig!
05. August 06:08 Deutsche Post: Prognosen geschlagen – kommt jetzt das Kaufsignal?
News im Fokus
Continental entwickelt sich in historisch schwachem zweiten Quartal besser als ihre Märkte
05. August 2020, 08:30
H1 2020 Results Analyst and Investor Call
05. August 2020
Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Kaufen Pharming Group NV
04. August 2020